NasdaqGS - Nasdaq Real Time Price USD

Karyopharm Therapeutics Inc. (KPTI)

6.01

-0.14

(-2.28%)

At close: May 9 at 4:00:00 PM EDT

5.75

-0.26

(-4.33%)

After hours: May 9 at 5:08:15 PM EDT

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report first quarter 2025 financial results on Monday, May 12, 2025. Karyopharm's management team will host a conference call and audio webcast at 4:30 p.m. ET on Monday, May 12, 2025, to discuss the financial results and other company updates.

PR Newswire 2 days ago

KPTI
-2.28%
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 983 restricted stock units (RSUs) to two newly-hired employees. These RSU awards were granted as of April 30, 2025 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq

PR Newswire 9 days ago

KPTI
-2.28%
Biotech stocks slide as Marks resignation seen being negative for sector

Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit

TipRanks last month

GLPG

GLPGF

PTCT
Karyopharm Announces 1-for-15 Reverse Stock Split

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will implement a 1-for-15 reverse stock split of the issued shares of the Company's common stock ("Reverse Stock Split"), effective at 5:00 p.m. Eastern Time on February 25, 2025. The Reverse Stock Split was approved by the Company's stockholders at the Company's Special Meeting of Stockholders held on January 30, 2025, with the final ratio subsequentl

PR Newswire 2 months ago

KPTI
-2.28%
Karyopharm Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Karyopharm Therapeutics ( NASDAQ:KPTI ) Full Year 2024 Results Key Financial Results Revenue: US$145.2m (flat on FY...

Simply Wall St. 2 months ago

KPTI
-2.28%
Karyopharm Therapeutics Inc (KPTI) Q4 2024 Earnings Call Highlights: Navigating Revenue ...

Karyopharm Therapeutics Inc (KPTI) reports a mixed financial performance with increased XPOVIO revenue and strategic progress in clinical trials amid revenue and cash flow challenges.

GuruFocus.com 2 months ago

KPTI
-2.28%
Q4 2024 Karyopharm Therapeutics Inc Earnings Call

Q4 2024 Karyopharm Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

KPTI
-2.28%
Karyopharm Therapeutics (KPTI) Q4 2024 Earnings Call Transcript

KPTI earnings call for the period ending December 31, 2024.

Motley Fool 2 months ago

KPTI
-2.28%
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 7.69% and 0.83%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

KPTI
-2.28%
Karyopharm Therapeutics: Q4 Earnings Snapshot

The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 26 cents per share. The pharmaceutical company posted revenue of $30.5 million in the period.

Associated Press Finance 2 months ago

KPTI
-2.28%
Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the fourth quarter and full year ended December 31, 2024. In addition, Karyopharm highlighted select corporate milestones and provided an overview of its key clinical development programs.

PR Newswire 2 months ago

KPTI
-2.28%
Analysts Estimate Indivior PLC (INDV) to Report a Decline in Earnings: What to Look Out for

Indivior (INDV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 months ago

INDV

KPTI
-2.28%
Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report fourth quarter and full year 2024 financial results on Wednesday, February 19, 2025. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Wednesday, February 19, 2025, to discuss the financial results and other company updates.

PR Newswire 2 months ago

KPTI
-2.28%
Verve Therapeutics (VERV) Moves 18.7% Higher: Will This Strength Last?

Verve Therapeutics (VERV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks 3 months ago

VERV

KPTI
-2.28%
Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2024 total revenue and U.S. XPOVIO net product revenue estimates and outlined its 2024 achievements and 2025 objectives.

PR Newswire 3 months ago

KPTI
-2.28%
Why Karyopharm Therapeutics (KPTI) Is Among the Best Penny Stocks to Invest In According to Media?

We recently compiled a list of the 12 Best Penny Stocks to Invest in According to the Media. In this article, we are going to take a look at where Karyopharm Therapeutics Inc. (NASDAQ:KPTI) stands against other best penny stocks to buy according to the media. Small-Cap Stocks Outlook for 2025 On December 24, Global […]

Insider Monkey 3 months ago

KPTI
-2.28%

^RUT

^GSPC
Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Lori Macomber as Executive Vice President, Chief Financial Officer and Treasurer, effective January 3, 2025. In this role, Ms. Macomber will be responsible for leading and directing the financial activities of the Company.

PR Newswire 4 months ago

KPTI
-2.28%
Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications.

PR Newswire 4 months ago

KPTI
-2.28%
Karyopharm Therapeutics Provides Endometrial Cancer Program Update

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it is in discussions and has an upcoming meeting with the U.S. Food and Drug Administration (FDA) regarding the evolving treatment landscape in endometrial cancer and any implications this may have with respect to the Company's Phase 3 XPORT-EC-042 trial. In light of this, Karyopharm does not plan to discuss its endometrial cancer program during the Piper

PR Newswire 5 months ago

KPTI
-2.28%
Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Piper Sandler 36th Annual Healthcare Conference in a fireside chat on Tuesday, December 3 at 11:30 a.m. ET in New York, NY.

PR Newswire 5 months ago

KPTI
-2.28%

Performance Overview

Return	KPTI	S&P 500 (^GSPC)
YTD	-40.73%	-3.77%
1-Year	-62.55%	+8.55%
3-Year	-92.07%	+41.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Karyopharm Therapeutics Inc. (KPTI)

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Biotech stocks slide as Marks resignation seen being negative for sector

Karyopharm Announces 1-for-15 Reverse Stock Split

Karyopharm Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Karyopharm Therapeutics Inc (KPTI) Q4 2024 Earnings Call Highlights: Navigating Revenue ...

Q4 2024 Karyopharm Therapeutics Inc Earnings Call

Karyopharm Therapeutics (KPTI) Q4 2024 Earnings Call Transcript

Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates

Karyopharm Therapeutics: Q4 Earnings Snapshot

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

Analysts Estimate Indivior PLC (INDV) to Report a Decline in Earnings: What to Look Out for

Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

Verve Therapeutics (VERV) Moves 18.7% Higher: Will This Strength Last?

Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives

Why Karyopharm Therapeutics (KPTI) Is Among the Best Penny Stocks to Invest In According to Media?

Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

Karyopharm Therapeutics Provides Endometrial Cancer Program Update

Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference

Performance Overview